Q4 2017 13F Holders as of 31 Dec 2017
-
Type / Class
-
Equity / Ordinary Shares, par value NIS 0.01 per share
-
Shares outstanding
-
46.2M
-
Number of holders
-
40
-
Total 13F shares, excl. options
-
5.74M
-
Shares change
-
+2.2M
-
Total reported value, excl. options
-
$214M
-
Value change
-
+$83.1M
-
Number of buys
-
25
-
Number of sells
-
-11
-
Price
-
$37.21
Significant Holders of UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN) as of Q4 2017
44 filings reported holding URGN - UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share as of Q4 2017.
UroGen Pharma Ltd. - Ordinary Shares, par value NIS 0.01 per share (URGN) has 40 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 5.74M shares
of 46.2M outstanding shares and own 12.42% of the company stock.
Largest 10 shareholders include MENORA MIVTACHIM HOLDINGS LTD. (1.51M shares), Consonance Capital Management LP (916K shares), FMR LLC (690K shares), WELLINGTON MANAGEMENT GROUP LLP (519K shares), MEITAV DASH INVESTMENTS LTD (413K shares), HIGHLINE CAPITAL MANAGEMENT, L.P. (400K shares), CREDIT SUISSE AG/ (224K shares), PERCEPTIVE ADVISORS LLC (199K shares), DSAM Partners (London) Ltd (137K shares), and RENAISSANCE TECHNOLOGIES LLC (131K shares).
This table shows the top 40 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.